Price Chart

Executive Summary

Apogee filed supplementary proxy materials (DEFA14A) on August 3, 2026, updating stockholders ahead of the August 11 special meeting to vote on the $135.11/share all-cash acquisition by AbbVie. The supplement addresses a pending stockholder lawsuit (Smith Complaint) alleging inadequate disclosures, adds voluntary disclosures on financial projections and fairness opinions, and confirms German antitrust clearance (FCO) was obtained on July 27, 2026, with an Australian ACCC filing underway. The board reiterates its unanimous recommendation for approval, and non-voting stock holders have already consented. The deal remains on track with the record-date share count updated to 62,140,183 voting shares outstanding; a majority of 31,070,092 votes is needed for approval.

Key Facts

• Merger consideration is $135.11 per share in cash, with Apogee stockholders to receive that amount upon closing
• Special meeting of stockholders to vote on the merger is scheduled for August 11, 2026 at 9:00 a.m. Eastern time
• As of the record date (July 10, 2026), there were 62,140,183 shares of voting common stock outstanding; directors and officers beneficially owned 1,412,999 shares (2.27%)
• Majority approval requires 31,070,092 affirmative votes; non-voting common stock holders have already delivered written consent to the merger
• One complaint filed in New York state court (Timothy Smith v. Apogee et al.) alleging inadequate disclosures; Apogee believes claims are without merit and is voluntarily making supplemental disclosures to mitigate litigation risk
• German Federal Cartel Office (FCO) provided unconditional clearance for the merger on July 27, 2026; an Australian ACCC notification was filed on the same date with a Phase 1 review period expiring September 7, 2026
• Goldman Sachs illustrative DCF analysis implied a per-share value range of $98.90 to $119.20; Jefferies precedent transactions analysis implied $117.65 to $151.35, with the $135.11 consideration falling within that range
• Management projections (2026-2046) show net sales beginning in 2029 ($106M) and rising to a peak of approximately $9.3B in 2038, driven by zumilokibart (APG777) for atopic dermatitis, eosinophilic esophagitis, and asthma, plus APG279
• Apogee had $1.358 billion in cash and cash equivalents and zero debt as of the valuation date, as used in Goldman Sachs’ DCF analysis
• Updated golden parachute compensation totals: CEO Michael Henderson ~$61.3M, Carl Dambkowski ~$25.6M, Jane Pritchett Henderson ~$25.3M (including equity, cash, perquisites, and tax reimbursement)

Financial Impact

Merger consideration of $135.11/share represents a significant premium over pre-announcement levels; implied enterprise value is approximately $10B+ based on $1.358B cash and zero debt. Management projects peak annual net sales of ~$9.3B by 2038.

Risk Factors

• The pending Smith Complaint could seek to delay or enjoin the merger, though Apogee believes the claims are without merit and is making supplemental disclosures to address them
• Failure to obtain remaining regulatory clearances (Australian ACCC, possibly others) could delay or prevent closing
• If a superior proposal emerges, Apogee's board could change its recommendation, though the merger agreement includes customary deal protection provisions
• Stockholder approval requires a majority of outstanding voting shares; abstentions and broker non-votes effectively count as votes against, creating a small risk of disapproval if turnout is low

Market Snapshot

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

US Market Status